Comprehensive clinical and molecular portraits of grade 3 ER+ HER-breast cancer

被引：2
|
作者：
Wang, K. [1 ]
Franch-Exposito, S. [2 ]
Li, L. [3 ]
Xiang, T. [4 ]
Wu, J. [3 ]
Ren, G. [4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing, Peoples R China
[2] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Gastrointestinal & Pancreat Oncol Team, Barcelona, Spain
[3] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China
[4] Chongqing Med Univ, Affiliated Hosp 1, Key Lab Mol Oncol & Epigenet, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.03.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
34P
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [1] Treatment of ER+/HER2+breast cancer
    Johnston, Stephen
    CANCER RESEARCH, 2023, 83 (05)
  • [2] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [3] Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer
    Mahdi, Amira F.
    Ashfield, Niall
    Crown, John
    Collins, Denis M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [4] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    CANCER RESEARCH, 2020, 80 (04)
  • [5] Targeted therapies for ER+/HER2-metastatic breast cancer
    Yamamoto-Ibusuki, Mutsuko
    Arnedos, Monica
    Andre, Fabrice
    BMC MEDICINE, 2015, 13
  • [6] Palbociclib Ups PFS in HER2-/ER+ Breast Cancer
    不详
    CANCER DISCOVERY, 2014, 4 (06) : 624 - 625
  • [7] Targeted therapies for ER+/HER2- metastatic breast cancer
    Mutsuko Yamamoto-Ibusuki
    Monica Arnedos
    Fabrice André
    BMC Medicine, 13
  • [8] Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer
    Elias, Anthony D.
    Staley, Alyse W.
    Fornier, Monica
    Vidal, Gregory A.
    Alami, Vida
    Sams, Sharon
    Spoelstra, Nicole S.
    Goodspeed, Andrew
    Kabos, Peter
    Diamond, Jennifer R.
    Shagisultanova, Elena
    Gallagher, Rosa I.
    Wulfkuhle, Julia D.
    Petricoin, Emanuel F.
    Zolman, Kathryn L.
    McSpadden, Tessa
    Jordan, Kimberly R.
    Slansky, Jill E.
    Borges, Virginia F.
    Gao, Dexiang
    Richer, Jennifer K.
    NPJ BREAST CANCER, 2024, 10 (01)
  • [9] Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
    Ciriello, Giovanni
    Gatza, Michael L.
    Beck, Andrew H.
    Wilkerson, Matthew D.
    Rhie, Suhn K.
    Pastore, Alessandro
    Zhang, Hailei
    McLellan, Michael
    Yau, Christina
    Kandoth, Cyriac
    Bowlby, Reanne
    Shen, Hui
    Hayat, Sikander
    Fieldhouse, Robert
    Lester, Susan C.
    Tse, Gary M. K.
    Factor, Rachel E.
    Collins, Laura C.
    Allison, Kimberly H.
    Chen, Yunn-Yi
    Jensen, Kristin
    Johnson, Nicole B.
    Oesterreich, Steffi
    Mills, Gordon B.
    Cherniack, Andrew D.
    Robertson, Gordon
    Benz, Christopher
    Sander, Chris
    Laird, Peter W.
    Hoadley, Katherine A.
    King, Tari A.
    Perou, Charles M.
    CELL, 2015, 163 (02) : 506 - 519
  • [10] β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER− breast cancer with HER2−
    Dandan Chai
    Kesheng Li
    Huifen Du
    Suisheng Yang
    Rong Yang
    Yang Xu
    Xiaowen Lian
    BMC Cancer, 19
12345